<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04914741</url>
  </required_header>
  <id_info>
    <org_study_id>20/047</org_study_id>
    <nct_id>NCT04914741</nct_id>
  </id_info>
  <brief_title>A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)</brief_title>
  <acronym>COALITION</acronym>
  <official_title>A Multicentre Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter MacCallum Cancer Centre, Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peter MacCallum Cancer Centre, Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multi-centre, phase Ib/II, parallel arm study evaluating the safety&#xD;
      and tolerability of glofitamab in addition to backbone chemotherapy consisting of R-CHOP or&#xD;
      polatuzumab vedotin-RCHP for younger patients with higher-risk Diffuse Large B-cell Lymphoma&#xD;
      or High Grade B-Cell Lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2021</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess safety of the combination of glofitamab and R-CHOP or pola-RCHP according to number of participants with treatment-related adverse events</measure>
    <time_frame>From start of treatment till the end of study, assessed up to approximately 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the Relative Dose Intensity (RDI) of the chemotherapy backbone</measure>
    <time_frame>From start of study treatment till the end of study treatment, assessed up to approximately 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the rates of early chemotherapy discontinuation</measure>
    <time_frame>From start of study treatment till the end of study treatment, assessed up to approximately 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate the proportion of patients achieving a complete response (CR) after cycles 2, 4 and at end of induction treatment (6 cycles) of the novel combination therapy according to Lugano 2014 criteria</measure>
    <time_frame>Up to approximately 6 months (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate overall response rate (ORR)</measure>
    <time_frame>Up to approximately 6 months (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe progression free survival (PFS)</measure>
    <time_frame>From first dose of chemotherapy induction to first date of objectively documented progressive disease or date of death of any cause, whichever occurs first, assessed up to approximately 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the duration of response (DoR) measured in the subset of patients who achieved CR or PR</measure>
    <time_frame>Time from the first documented disease response to the date of progressive disease or death, whichever occurs first, assessed up to approximately 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) as defined as the time from first dose of chemotherapy induction to the date of death from any cause</measure>
    <time_frame>From first dose of chemotherapy induction to the date of death from any cause, assessed up to approximately 60 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation between circulating tumour DNA detection and response (CR and ORR)</measure>
    <time_frame>From start of treatment till end of study assessed up to 60 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of efficacy (rates of CR, ORR, DOR, PFS and OS) between the two study arms</measure>
    <time_frame>From start of treatment till end of study assessed up to 60 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>High-grade B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Glofitamab plus R-CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive treatment in 21 day cycles consisting of R-CHOP in cycle 1, followed by R-CHOP plus glofitamab for cycles 2-6, and two cycles of glofitamab monotherapy consolidation. Patients may also receive high-dose methotrexate CNS prophylaxis at investigator discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glofitamab plus polatuzumab vedotin-RCHP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive treatment in 21 day cycles consisting of R-CHOP in cycle 1, followed by polatuzumab vedotin-RCHP plus glofitamab for cycles 2-6, and two cycles of glofitamab monotherapy consolidation. Patients may also receive high-dose methotrexate CNS prophylaxis at investigator discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 375 mg/m^2 administered by IV infusion on Day 1 of every 21-day cycle</description>
    <arm_group_label>Glofitamab plus R-CHOP</arm_group_label>
    <arm_group_label>Glofitamab plus polatuzumab vedotin-RCHP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 750mg/m^2 administered by IV infusion on Day 1 of every 21-day cycle</description>
    <arm_group_label>Glofitamab plus R-CHOP</arm_group_label>
    <arm_group_label>Glofitamab plus polatuzumab vedotin-RCHP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 50mg/m^2 administered by IV infusion on Day 1 of every 21-day cycle</description>
    <arm_group_label>Glofitamab plus R-CHOP</arm_group_label>
    <arm_group_label>Glofitamab plus polatuzumab vedotin-RCHP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine 1.4mg/m^2 administered by IV infusion on Day 1 of every 21-day cycle</description>
    <arm_group_label>Glofitamab plus R-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone 100mg orally on Days 1-5 of every 21-day cycle</description>
    <arm_group_label>Glofitamab plus R-CHOP</arm_group_label>
    <arm_group_label>Glofitamab plus polatuzumab vedotin-RCHP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glofitamab</intervention_name>
    <description>Glofitamab will be administered by IV infusion as per the schedule specified in the respective arm</description>
    <arm_group_label>Glofitamab plus R-CHOP</arm_group_label>
    <arm_group_label>Glofitamab plus polatuzumab vedotin-RCHP</arm_group_label>
    <other_name>RO7082859</other_name>
    <other_name>CD20-TCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polatuzumab vedotin</intervention_name>
    <description>Polatuzumab 1.8mg/kg administered by IV infusion on Day 1 of every 21-day cycle</description>
    <arm_group_label>Glofitamab plus polatuzumab vedotin-RCHP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18yo and ≤65yo at the time of signing consent&#xD;
&#xD;
          2. Have a histologically confirmed diagnosis of one of the following, according to the&#xD;
             2016 WHO classification:&#xD;
&#xD;
               1. DLBCL, NOS or DLBCL arising as a result of transformation of an indolent lymphoma&#xD;
&#xD;
               2. HGBL, NOS&#xD;
&#xD;
               3. HGBL with rearrangements of MYC and BCL2 and/or BCL6&#xD;
&#xD;
          3. For DLBCL, and HGBL, NOS meets one of the following risk criteria:&#xD;
&#xD;
             a. NCCN-IPI of ≥4 or IPI ≥3 (appendix 1 and 3)&#xD;
&#xD;
          4. Considered fit for 6 cycles of full dose R-CHOP chemotherapy, as per the Investigator&#xD;
&#xD;
          5. ECOG performance status (appendix 5) of:&#xD;
&#xD;
               1. 0-2 inclusive or 3 if directly attributable to lymphoma for patients entering the&#xD;
                  trial prior to cycle 1 of R-CHOP&#xD;
&#xD;
               2. 0-1 inclusive for patients entering the trial at cycle 2&#xD;
&#xD;
          6. Patients must be treatment-naïve or have received a maximum of one cycle of full-dose&#xD;
             R-CHOP chemotherapy (with or without a steroid pre-phase)&#xD;
&#xD;
          7. Able to provide an archival pre-treatment biopsy.&#xD;
&#xD;
          8. Have measurable disease on a pre-chemotherapy PET/CT, defined as at least one&#xD;
             bi-dimensionally measurable nodal lesion of &gt;1.5cm in longest dimension, or at least&#xD;
             one bi-dimensionally measurable extranodal lesion of &gt;1.0cm in longest dimension&#xD;
&#xD;
          9. Life expectancy (in the opinion of the Investigator) of ≥ 18 weeks&#xD;
&#xD;
         10. Adequate haematological function&#xD;
&#xD;
         11. Adequate renal function&#xD;
&#xD;
         12. Adequate hepatic function&#xD;
&#xD;
         13. Negative serologic or PCR test results for active acute or chronic HBV infection.&#xD;
&#xD;
         14. Non-haematological AEs from prior anti-cancer therapy must have resolved to Grade ≤1&#xD;
             (with the exception of alopecia and inclusion criteria 10-12)&#xD;
&#xD;
         15. Negative test results for HCV and HIV.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to comply with protocol mandated hospitalisations and restrictions&#xD;
&#xD;
          2. Prior systemic treatment of an underlying indolent lymphoma with an&#xD;
             anthracycline-containing regimen&#xD;
&#xD;
          3. Richter's syndrome&#xD;
&#xD;
          4. Patients with known CNS involvement by lymphoma&#xD;
&#xD;
          5. With the exception of rituximab, any prior treatment with systemic immunotherapeutic&#xD;
             agents, including, but not limited to, radio-immuno-conjugates, antibody-drug&#xD;
             conjugates, immune/cytokines, and monoclonal antibodies within 4 weeks or five&#xD;
             half-lives of the drug, whichever is shorter, before the first dose of study drug&#xD;
&#xD;
          6. With the exception of CHOP used as a first cycle of lymphoma treatment, any&#xD;
             chemotherapeutic agent, or treatment with any other investigational agent within 4&#xD;
             weeks prior to study treatment&#xD;
&#xD;
          7. Prior solid organ transplantation&#xD;
&#xD;
          8. Prior autologous or allogeneic stem cell transplantation&#xD;
&#xD;
          9. A history of treatment-emergent immune related AEs associated with prior&#xD;
             immunotherapeutic agents&#xD;
&#xD;
         10. Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or&#xD;
             neurodegenerative disease&#xD;
&#xD;
               1. Note: patients with a history of stroke who have not experienced a stroke or&#xD;
                  transient ischaemic attack in the past 2 years are allowed&#xD;
&#xD;
               2. Note: patients with a history of epilepsy who have not experienced a seizure in&#xD;
                  the past 2 years are allowed, so long as continuation of any ongoing established&#xD;
                  pharmacologic treatment is not contraindicated&#xD;
&#xD;
         11. Past history of confirmed progressive multifocal leukoencephalopathy&#xD;
&#xD;
         12. Past history of chronic active EBV or HLH&#xD;
&#xD;
         13. Major surgery or significant traumatic injury &lt;28 days prior to study treatment or&#xD;
             anticipation of the need for major surgery during study treatment&#xD;
&#xD;
         14. Significant cardiovascular disease, defined as:&#xD;
&#xD;
               1. A left ventricular ejection fraction (as determined by nuclear gated blood pool&#xD;
                  scan or echocardiogram) &lt;50%&#xD;
&#xD;
               2. Myocardial infarction or unstable angina within the past 6 months&#xD;
&#xD;
               3. Unstable arrhythmia&#xD;
&#xD;
               4. Any other cardiac illness that, in the opinion of the Investigator or CPI, makes&#xD;
                  the patient unsuitable for anthracycline containing therapy&#xD;
&#xD;
         15. Significant pulmonary disease, including but not limited to clinically significant&#xD;
             obstructive pulmonary disease or history of bronchospasm&#xD;
&#xD;
         16. Current grade &gt;1 peripheral neuropathy by clinical examination or demyelinating form&#xD;
             of Charcot-Marie-Tooth disease&#xD;
&#xD;
         17. Known clinically significant liver disease, including active viral or other hepatitis,&#xD;
             current alcohol abuse, or cirrhosis&#xD;
&#xD;
         18. Administration of a live, attenuated vaccine within 4 weeks before study treatment&#xD;
             note: influenza vaccination should be given during influenza season only. Patients&#xD;
             must not receive live, attenuated influenza vaccine at any time during the study&#xD;
             treatment period&#xD;
&#xD;
         19. History of other active malignancy within 5 years prior to registration, with the&#xD;
             exception of:&#xD;
&#xD;
               1. FL or MZL, previously untreated, or treated with no more than one line of therapy&#xD;
                  which must not have contained an anthracycline&#xD;
&#xD;
               2. Basal or squamous cell carcinoma or Stage 1 melanoma of the skin or in situ&#xD;
                  carcinoma of the cervix&#xD;
&#xD;
               3. Prior malignancy treated with a curative intent that has remained in remission&#xD;
                  without treatment for ≥2 years prior to registration&#xD;
&#xD;
         20. Patients with known active bacterial, viral, fungal, mycobacterial, parasitic, or&#xD;
             other infection (excluding fungal infections of the nail beds) at registration&#xD;
&#xD;
             a. Note: Patients with latent tuberculosis are excluded&#xD;
&#xD;
         21. Other significant life-threatening illness or medical condition which, in the&#xD;
             Investigator's opinion, could compromise the patient's safety, interfere with&#xD;
             absorption or metabolism of study drug, affect compliance with the protocol or&#xD;
             interpretation of results, or put the study outcomes at undue risk&#xD;
&#xD;
         22. Major contraindication to any of the individual components of the chemotherapy&#xD;
             backbone (R, C, H, O, Polatuzumab vedotin, prednisolone)&#xD;
&#xD;
         23. Patients who are pregnant or breastfeeding&#xD;
&#xD;
        Other protocol-defined inclusion and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Dickinson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peter MacCallum Cancer Centre &amp; Royal Melbourne Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Dickinson</last_name>
    <phone>+61385597858</phone>
    <email>michael.dickinson@petermac.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adrian Minson</last_name>
    <phone>+61385598309</phone>
    <email>adrian.minson@petermac.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Minson</last_name>
      <email>adrian.minson@petermac.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shu Min Wong</last_name>
      <email>shu.wong@alfred.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Epworth Healthcare</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Costas Yannakou</last_name>
      <email>costas.yannakou@epworth.org.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLBCL</keyword>
  <keyword>HGBL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

